Immunomedics Sales Force In Europe
US company Immunomedics has hired its first sales representative forGermany, Austria and Switzerland to sell LeukoScan, its radiolabeled monoclonal antibody fragment for the detection of infectious diseases.
The product is already launched in Germany and Austria (Marketletter April 28), and the company is preparing an application for marketing approval in Switzerland for LeukoScan, which is already approved in the European Union for diagnosing osteomyelitis.
The European filing for a second indication, the diagnosis of acute non-classic appendicitis, is not yet approvable, noted Immunomedics. The firm has to clarify the clinical setting in which the product will be used, among other items.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze